术中超声引导放射性125I粒子组织间植入治疗局部晚期胰腺癌

目的探讨超声引导下术中放射性125I粒子组织间种植治疗无法切除胰腺癌的可行性和疗效. 方法 2002年4月～2005年2月,我院行开腹125I粒子植入治疗晚期胰腺癌21例.术前根据治疗计划,确定粒子活度和种植粒子个数,肿瘤匹配周边剂量为65～110 Gy,每颗粒子活度为0.4～0.5 mCi.超声引导下插入粒子种植针,Mick粒子植入器植入125I粒子,粒子植入数10～75颗.8例粒子植入前或后行胃肠或胆肠吻合术.2例术后行外放疗联合单药吉西他滨化疗.1例术前置入支架,1例术后置入支架. 结果 15例腹痛中,14例术后1～3 d疼痛即开始缓解,其中7例疼痛完全缓解,7例部分缓解,1例无效,有效率93.3%(14/15);除2例失访外,CR 5例,PR 7例,PD 5例,NC 2例.19例中位生存期5个月,1年生存率26.3%.1例出现乳糜漏,3例粒子移位到肝脏.无胰漏和胰腺炎等并发症. 结论放射性125I粒子组织间种植治疗胰腺癌具有安全、有效、创伤小和并发症发生率低等优点,是一种较好的补救治疗手段.

Ultrasound-guided interstitial 125I seed implantation in the treatment of locally advanced pancreatic carcinoma

Objective To investigate the feasibility and efficacy of ultrasound-guided interstitial implantation of radioactive ~(125)I seed for the treatment of unresectable pancreatic carcinoma.Methods Twenty-one patients with unresectable primary pancreatic carcinoma were treated with interstitial ~(125)I seed implantation under laparotomy.The radioactive activity and the number of implanted seed were determined according to preoperative CT scanning outcomes by using the Treatment Planning System(TPS).The matched peripheral dose(MPD) was 65~110 Gy.The radioactive activity ranged 0.4~0.5 mCi per seed.A total of 10~75 ~(125)I seed were implanted with an 18-gauge seed needle and the Mick applicator under direct visualization or ultrasound guidance.Gastroenterostomy or cholangiojejunostomy were performed in 8 patients before or after the implantation.Postoperative external radiation therapy combined with chemotherapy with gemcitabine was carried out in 2 patients. Stent placement was conducted in 2 patients preoperatively and postoperatively, respectively.Results Out of 15 patients with abdominal pain,complete and partial pain relief were obtained in 7 patients and 7 patients,respectively,at 1~3 postoperative days,the response rate being 93.3%(14/15). Except for 2 cases of loss of follow-up,there were 5 cases of complete response(CR),7 cases of partial response(PR),5 cases of progressive disease(PD),and 2 cases of no change(NC).Of 19 patients,the median survival time was 5 months and the 1-year survival rate was 26.3%.Chylous leakage occurred in 1 patient and seed dislodgement to the liver occurred in 3 patients.No pancreatic fistula or pancreatitis were encountered. Conclusions Radioactive ~(125)I seed implantation for the treatment of pancreatic carcinoma is safe,effective,and micro-invasive,being a good option of remedy.